Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from ME Therapeutics Holdings, Inc. ( (TSE:METX) ) is now available.
ME Therapeutics Holdings Inc. has announced promising results for its first therapeutic mRNA candidate, developed in collaboration with NanoVation Therapeutics, which shows encouraging anti-cancer activity in a mouse model of colorectal cancer. As a result of these findings, ME Therapeutics plans to expand its therapeutic mRNA research and development program to further explore the mechanism of action and enhance therapeutic efficacy, which signifies a positive step forward in the company’s focus on novel cancer treatments and its strategic position in the biotechnology sector.
More about ME Therapeutics Holdings, Inc.
Myeloid Enhancement (ME) Therapeutics is a preclinical stage biotechnology company based in Vancouver, specializing in the discovery and development of novel immuno-oncology therapeutics. The company focuses on overcoming immune suppression in cancer by targeting myeloid cells to enhance anti-cancer immunity.
YTD Price Performance: -5.00%
Average Trading Volume: 1,246
Technical Sentiment Consensus Rating: Strong Sell
For a thorough assessment of METX stock, go to TipRanks’ Stock Analysis page.